TACSTD2 and malignant colon neoplasm: In our analysis we also found TACSTD2 to be highly expressed in many colon cancer samples and shows bimodality (Additional file 1, Figure S6), however the percentage of colon cancer samples with TACSTD2 at the ON state (~60%) are less than in breast cancer (~99%), suggesting TACSTD2 could be a better target for breast cancer.